Wren Therapeutics secures £18 million in funding to tackle protein misfolding diseases
A biopharmaceutical company set-up by Cambridge academics from St John's College to develop drugs to treat illnesses such as Alzheimer's, Parkinson’s and more than 50 other related diseases has won £18 million in a Series A financing round.
Wren Therapeutics raised the funding from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of high net worth individual investors.
Several of the company’s scientific founders are members of St John’s, including Professor Sir Christopher Dobson, Master of St John's, Professor Tuomas Knowles, a St John's Fellow, and Dr Samuel Cohen, the St John’s Entrepreneur in Residence.
Wren Therapeutics focuses on drug discovery and development for protein misfolding diseases such as Alzheimer’s and Parkinson’s and was founded in 2016.
"I am hugely enthusiastic about our ability to make tangible progress against these diseases"
Professor Sir Christopher Dobson
To read the full article, please visit the University of Cambridge website.